An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Nexletol

Chemical Namebempedoic acid
Dosage FormTablet (oral; 180 mg)
Drug ClassInhibitors
SystemCardiovascular
CompanyEsperion
Approval Year2020

Indication

  • Nexletol is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Last updated on 10/20/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nexletol (bempedoic acid) Prescribing Information2020Esperion
Document TitleYearSource
Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis.2020PLOS Medicine
Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials.2020Sage Journals
Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis.2020Cardiovascular Diabetology
Efficacy and safety of bempedoic acid in Patients with hypercholesterolemia: systematic review and meta‐analysis of randomized controlled trials.2020Journal of the American Heart Association